Background The endothelium synthesizes and releases a relaxing factor with the physiochemical properties of nitric oxide (NO). However, the role of endothelium-derived NO in the basal regulation of systemic and pulmonary vascular resistance in humans is not known. Our primary objectives were to determine the effects of inhibiting NO synthesis on blood pressure and systemic vascular resistance and to establish the role of endothelium-derived NO in the regulation of normoxic pulmonary vascular tone.
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Methods and Results We studied the systemic and pulmonary hemodynamic effects of N0-monomethyl-L-arginine (L-NMMA, 0.03 to 1.0 mg . kg.* min-IV), an NO synthase inhibitor, in 11 healthy volunteers, aged 33±2 years. An arterial cannula and a pulmonary artery catheter were placed in each subject to measure blood pressure, pulmonary artery pressure, and pulmonary capillary wedge pressure. Cardiac output was determined by the Fick technique, and systemic and pulmonary vascular resistances were calculated. Serum NO levels (free and protein bound) were measured by chemiluminescence in 5 subjects. Six of the subjects also received phenylephrine (25 to 100 ,ug/min IV) to compare the cardiac hemodynamic effects of L-NMMA with those of a direct-acting vasoconstrictor. L-NMMA caused dose-dependent increases in both blood pressure and systemic vascular resistance. At the highest dose of L-NMMA, there was a 15.5+1.3% increase in mean blood pressure and a 63.4±8.2% increase in systemic vascular resistance ( As a result, the amino acid L-arginine is converted enzymatically to NO through oxidation of its guanidium nitrogen.3-5 The elucidation of this biochemical mechanism has led to the development of arginine analogues, such as NG-monomethyl-L-arginine (L-NMMA), which stereospecifically inhibit NO production in vascular tissue.3-5 Recent studies have shown that systemic infusion of L-NMMA in laboratory animals increases blood pressure, suggesting that tonic release of NO contributes to vascular resistance in the systemic arterial bed.6-10 Although these observations are supported in humans by the finding that limb vascular resistance increases during intrabrachial-arterial infusion of L-NMMA,"1 inhibitors of NO synthesis have not been administered systemically to healthy subjects. Therefore, the role of endothelium-derived NO in the basal regulation of blood pressure homeostasis is not known.
The pulmonary vasculature is a unique low-pressure system with a special capacity to adapt to local changes in blood flow. Both pulmonary arterial and venous endothelia secrete NO constitutively and in response to a variety of physiological and chemical stimuli.12-'4 It is well established that impairment of endogenous NO release, whether due to structural endothelial disease or induced pharmacologically, is associated with enhanced responsiveness to vasoconstrictor stimuli in pulmonary vessels.14-'7 There also is a growing consensus that endothelial dysfunction may contribute to the pathogenesis of pulmonary hypertension.'3,'4,'6 Notwithstanding the potential importance of endogenous NO in modulation of pulmonary vascular reactivity, its effects on normoxic basal tone have yielded conflicting results, and species specificity exists.'0"18-3' Thus, the fundamental question as to whether endothelium-derived NO contributes to the maintenance of normal pulmonary tone in humans remains unanswered. 
Experimental Protocol
All subjects rested at least 30 minutes after catheter placement to establish a stable baseline before data collection. During the control period, hemodynamic measurements were repeated every 10 minutes until stable. During this period, vehicle (dextrose 5%) was infused via the side arm of the internal jugular vein sheath. To assess the effect of endothelium-derived NO on basal SVR and PVR, we administered L-NMMA (Calbiochem, Inc) in dosages of 0.01, 0.03, 0.1, 0.3, and 1.0 mg * kg-' * min' , each for 3 minutes (by which time the maximal response was achieved), delivered at a rate of 3.9 mL/min, via the side arm of the central venous catheter sheath. The dose range of L-NMMA used systemically in this study was based on knowledge derived from experiments in which L-NMMA was infused intra-arterially at dosages of approximately 1 mg/min for 5 to 20 minutes into the human forearm in our laboratory32 and by others1' and is comparable to that studied in patients with septic shock.33 Hemodynamic measurements were made and blood was collected for arterial and mixed venous oxygen saturation at the end of each infusion period. Steady state was verified by repeating hemodynamic measurements 10 minutes after the last dose of L-NMMA. To compare the hemodynamic effects of L-NMMA with those of a direct-acting vasoconstrictor, 6 of the subjects also received phenylephrine via the central venous catheter at dosages of 25, 50, 75, and 100 1£g/min each for 3 minutes at a rate of 0.3 to 1.3 mL/min. Hemodynamic measurements were made and blood was collected for measurements of oxygen saturation after each dose was administered. The phenylephrine infusion was terminated if MBP increased by 20%. Two of the subjects received L-NMMA and phenylephrine on separate days, whereas in 4 subjects, both phenylephrine and L-NMMA were administered in sequence on the same day. In this latter group of subjects, baseline conditions were reestablished before L-NMMA was administered. No adverse effects were observed in any patient during infusion of either L-NMMA or phenylephrine.
Plasma NO Determination
The predominant bioactive reservoir of NO in human plasma is bound to protein thiol groups, and these levels correlate well with endogenous NO production.34 Plasma NO levels were measured in 5 subjects at baseline (before L-NMMA) and immediately after administration of the highest dose of L-NMMA. Platelet-poor plasma was first obtained by centrifugation at 800g for 10 (Fig 1) . The (P<.01) (Fig 2) . There was no demonstrable change in PCWP at any dose of L-NMMA.
Administration of L-NMMA resulted in a dosedependent decline in CI and SVI in all subjects; at the highest dose of L-NMMA, CI decreased by 27 1.3±2.0 mL * min'* m-', respectively (P<.01 between drugs) (Fig 4) .
Discussion
Our study demonstrates that in healthy humans, (1) endothelium-derived NO is continuously released from both the systemic and pulmonary arterial circulations; (2) basal release of NO is directly involved in the determination of SVR and, therefore, blood pressure; (3) NO regulates basal normoxic pulmonary vascular tone; and (4) constitutive release of NO is required to maintain normal CO. Thus, the complex hemodynamic effects of NO are a composite property of its actions on both arterial tone and cardiac function. NO Regulates SVR and PVR Infusion of L-NMMA resulted in a marked increase in SVR. Indeed, our results are generally consistent with studies in lower mammals6-'020 and support the notion that tonic NO production by the endothelium is an important determinant of resting blood pressure. These observations also extend the earlier findings of Valiance et al,"1 showing that infusion of L-NMMA into the brachial artery of healthy volunteers causes a decline in basal forearm blood flow. Taken together with this study, our findings definitively establish the functional importance of the endothelium-derived relaxing factor NO in both local and systemic regulation of basal arteriolar tone. The mechanism(s) by which low pressure and vascular resistance are maintained in the pulmonary circulation are poorly understood. The finding that L-arginine analogues increase basal tone in prestimulated pulmonary vascular rings16'25'35'36 and modulate responsiveness to constrictor stimuli12-'4,18 has led to the hypothesis that endothelium-derived NO release is an important etiological factor. However, studies in laboratory animals are divergent with regard to the importance of the effect of endogenous NO on basal pulmonary vascular tone. In the cat,19,29 lamb,1'522'27 and ovine fetus,2' inhibition of the L-arginine-NO pathway is associated with an increase in vascular tone, whereas either variable or no effect has been observed in the rat,23,26 rabbit,2428 and dog. 18'2025 In light of species differences, the physiological role of NO in basal regulation of pulmonary tone in humans has remained uncertain. Notably, we observed an increase in PVR in response to systemic infusion of L-NMMA without an effect on cardiac filling pressures, indicating that NO release is an important determinant of resting pulmonary artery tone in humans. The lack of change in PAP may be explained by the concomitant decrease in CO. In addition, most recent data suggest that L-NMMA is a relatively ineffective inhibitor of NO synthase in pulmonary blood vessels,37 findings compatible with the more pronounced effects seen in the systemic circulation and with the growing evidence for enzyme inhibitor specificity.3'5 Effect of L-NMMA on CO Systemic inhibition of NO production was associated with a decline in CO and SV. Similar results have been reported in dogs, rats, and sheep. [8] [9] [10] 2038 The most plausible explanations include a baroreceptor reflex response to increases in arterial pressure, depression of SV due to increased afterload (without concomitant change in cardiac filling pressures), a basal myocardial NO requirement for normal contractile function, and myocardial ischemia due to coronary vasoconstriction. We exclude the last possibility with reasonable confidence as continuous ECG monitoring did not reveal ischemic changes and all subjects were free of chest pain; furthermore, intracoronary L-NMMA infusions in dogs38 and humans39 have not been associated with ischemia. It seems likely that the increase in blood pressure initiated a baroreceptor reflex, resulting in withdrawal of sympathetic efferent activity and augmentation of vagal activity, since HR decreased. The decrease in CO, however, seemed greater than we might have anticipated simply from withdrawal of sympathetic activity. We queried whether the increased afterload depressed SV. To address these possibilities further, phenylephrine was infused to increase arterial pressure to a level comparable to that resulting from L-NMMA.
We observed a modest decline in CO and no significant change in SV in the subjects who received phenylephrine. Indeed, the decrease in SV was substantially less than that which occurred with comparable pressor doses of L-NMMA. Our findings are consistent with a report in intact dogs in which depression of CO by L-NMMA exceeded that observed with phenylephrine.38 These observations suggest that the effect of L-NMMA on cardiac function is multifactorial and cannot be explained solely by the increase in blood pressure. Recognizing that the comparisons made are limited by the potentially mild inotropic actions of phenylephrine,40 we are therefore faced with the more controversial possibility that some basal constitutive (endo)myocardial or neuronal release of NO is required to preserve cardiac function in vivo. At the same time, we do not discount the evidence that NO production by the constitutive NO synthase may also play a feedback-inhibitory role in myocytes to modulate the contractile response. [41] [42] [43] Moreover, in inflammatory settings-such as myocarditis or endotoxic shock-the cytokine-mediated induction of high-output NO generation may directly contribute to myocardial depression.42,4"445 Effect of L-NMMA on Plasma NO Levels
We have recently shown that NO exists in human plasma predominantly in adduct form with the thiol group of albumin.34 Most recent data derived from plasma and other systems suggest that levels of S-nitrosothiol are in the range of 0.1 to 0.5 liM, approximately two orders of magnitude higher than free NO."6 These S-nitrosoproteins possess vasorelaxant activity at physiologically relevant concentrations and are envisioned to play a bufferlike function, serving as a source and a sink for free NO to modulate rapid changes in vasomotor tone.?"47 In rabbits, infusion of L-NMMA is associated with a decrease in plasma NO content that parallels the increase in blood pressure?4 That we demonstrate the same for humans in this study both confirms the inhibition of endogenous NO synthesis and supports the notion that S-nitrosoprotein levels may be used to monitor changes in NO production in other diverse pathophysiological states.
Conclusions
Our findings have several fundamentally important implications. The conclusion that NO is continuously released to maintain normal pulmonary artery tone, systemic arterial pressure, and CO suggests that compromise of the normal constitutive mechanisms of NO synthesis may have direct pathophysiological consequences. As proposed by Moncada and colleagues,48 certain classes of (essential) hypertension may be better classified as states of "hypovasodilitation"; a defect in NO production in certain patients with hypertension is consistent with this proposal. By analogy, alterations in NO synthesis transport or signaling may be important etiological factors in the development of pulmonary "hypertension," consequent cor pulmonale, and even compromise in left ventricular systolic function. Importantly, the endothelium and endocardium are not the sole sources of constitutive NO production.3-5 Thus, in addition to dysfunction of the endothelium, primary abnormalities of the "nitrinergic" (nonadrenergic, noncholinergic) nervous system47 and perhaps of the platelet or neutrophil49 deserve consideration in the pathogenesis of abnormal vascular reactivity and cardiac pump function.
